Can a CPT Violating Ether Solve ALL Electron (Anti)Neutrino Puzzles?

Assuming that CPT is violated in the neutrino sector seems to be a viable alternative to sterile neutrinos when it comes to reconciling the LSND anomaly with the remainder of the neutrino data. There are different (distinguishable) ways of incorporating CPT violation into the standard model, including postulating m different from \bar{m}. Here, I investigate the possibility of introducing CPT violation via Lorentz-invariance violating effective operators (``Ether'' potentials) which modify neutrino oscillation patterns like ordinary matter effects. I argue that, within a simplified two-flavor like oscillation analysis, one cannot solve the solar neutrino puzzle and LSND anomaly while still respecting constraints imposed by other neutrino experiments, and comment on whether significant improvements should be expected from a three-flavor analysis. If one turns the picture upside down, some of the most severe constrains on such CPT violating terms can already be obtained from the current neutrino data, while much more severe constraints can arise from future neutrino oscillation experiments.Comment: 10 pages, 1 eps figure; version to appear in PRD. Comment added, mistake corrected, results and conclusions unchange

Nucleon to Delta Weak Excitation Amplitudes in the Non-relativistic Quark Model

We investigate the nucleon to Delta(1232) vector and axial vector amplitudes in the non-relativistic quark model of the Isgur-Karl variety. A particular interest is to investigate the SU(6) symmetry breaking, due to color hyperfine interaction. We compare the theoretical estimates to recent experimental investigation of the Adler amplitudes by neutrino scattering.Comment: \documentstyle[aps]{revtex}, 21pages; 11 postscript figures. Accepted for publication by Phys. Rev.

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

BACKGROUND Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and inter-leukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn’s disease. Ustekinumab was also evaluated as subcutaneous maintenance therapy. METHODS We randomly assigned patients to receive a single intravenous dose of ustekinumab (either 130 mg or approximately 6 mg per kilogram of body weight) or placebo in two induction trials. The UNITI-1 trial included 741 patients who met the criteria for primary or secondary nonresponse to tumor necrosis factor (TNF) antagonists or had unacceptable side effects. The UNITI-2 trial included 628 patients in whom conventional therapy failed or unacceptable side effects occurred. Patients who completed these induction trials then participated in IM-UNITI, in which the 397 patients who had a response to ustekinumab were randomly assigned to receive subcutaneous maintenance injections of 90 mg of ustekinumab (either every 8 weeks or every 12 weeks) or placebo. The primary end point for the induction trials was a clinical response at week 6 (defined as a decrease from baseline in the Crohn’s Disease Activity Index [CDAI] score of ≥100 points or a CDAI score <150). The primary end point for the maintenance trial was remission at week 44 (CDAI score <150). RESULTS The rates of response at week 6 among patients receiving intravenous ustekinumab at a dose of either 130 mg or approximately 6 mg per kilogram were significantly higher than the rates among patients receiving placebo (in UNITI-1, 34.3%, 33.7%, and 21.5%, respectively, with P≤0.003 for both comparisons with placebo; in UNITI-2, 51.7%, 55.5%, and 28.7%, respectively, with P<0.001 for both doses). In the groups receiving maintenance doses of ustekinumab every 8 weeks or every 12 weeks, 53.1% and 48.8%, respectively, were in remission at week 44, as compared with 35.9% of those receiving placebo (P = 0.005 and P = 0.04, respectively). Within each trial, adverse-event rates were similar among treatment groups. CONCLUSIONS Among patients with moderately to severely active Crohn’s disease, those receiving intravenous ustekinumab had a significantly higher rate of response than did those receiving placebo. Subcutaneous ustekinumab maintained remission in patients who had a clinical response to induction therapy. (Funded by Janssen Research and Development; ClinicalTrials.gov numbers, NCT01369329, NCT01369342, and NCT01369355.

Quiet time observations of the open-closed boundary prior to the CIR-induced storm of 9 August 2008

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/95511/1/swe467.pd